Glenmark Pharmaceuticals, a global pharmaceutical company will initiate clinical study for GBR 1342. The US Food and Drug Administration (USFDA) cleared the company’s Investigational New Drug (IND) application to initiate a Phase 1 study of GBR 1342, a humanized, bispecific monoclonal antibody (bsAb) being studied for the treatment of multiple myeloma in patients who have received prior therapies.
GBR 1342 is designed to activate the patient’s immune system by redirecting immune cells towards tumor tissue, which may lead to targeted destruction of tumors. It is based on Glenmark’s proprietary BEAT (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform.
The first-in-human Phase 1 study of GBR 1342 will enroll subjects with multiple myeloma who have exhausted available therapies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.00 |
| Dr. Reddys Lab | 1220.00 |
| Cipla | 1231.00 |
| Zydus Lifesciences | 928.25 |
| Lupin | 2322.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: